Key result
Single-cell transcriptomics delineate distinct placenta-dominant and maternal cardiovascular-dominant preeclampsia subtypes.
Answers are grounded in this paper and cite their sources.
Genomic research using single-cell transcriptomics supports the existence of two distinct preeclampsia subtypes, which may guide future biomarker discovery and targeted management.
Recent advances in single-cell transcriptomics have provided significant insights into the pathophysiology of preeclampsia, uncovering cell-type-specific gene expression changes at the maternal-fetal interface. Key discoveries include dysregulated angiogenic factors, such as elevated sFlt-1 (soluble fms-like tyrosine kinase-1) and reduced PlGF (placental growth factor), predominantly in syncytiotrophoblasts, alongside inflammatory and stress-related signatures in stromal and immune cells. These findings reinforce the clinically observed concept of 2 distinct preeclampsia subtypes: a placenta-dominant form and a maternal cardiovascular-dominant form, each characterized by unique etiologies, clinical presentations, and therapeutic implications. Ongoing genomic research has the potential to identify novel biomarkers and therapeutic targets, paving the way for improved screening and management strategies for this multifaceted condition.
No takes yet. Share an insight, caveat, or question.
Solt et al. (2025) conducted a review in Preeclampsia. Single-cell transcriptomics was evaluated. Single-cell transcriptomics reveal cell-type-specific gene expression changes, reinforcing the concept of placenta-dominant and maternal cardiovascular-dominant preeclampsia subtypes.
Synapse has enriched 10 related papers. Consider them for comparative context: